MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13506129.2018.1449744

Медицинская библиотека · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2018

Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

Muchtar Eli, Gertz Morie A, Kumar Shaji K, Lin Grace, Boilson Barry, Clavell Alfredo, Lacy Martha Q, Buadi Francis K, Hayman Suzanne R, Kapoor Prashant, Dingli David, Rajkumar S Vincent, Dispenzieri Angela, Grogan Martha

СтатьяПеревод в очереди

Аннотация

AIM: Digoxin is considered contraindicated in light-chain (AL) amyloidosis, given reports of increased toxicity published 30-50 years ago. We sought to determine the frequency of digoxin toxicity in patients with AL.

METHODS

We identified 107 patients with AL amyloidosis who received digoxin between 2000 and 2015.

RESULTS

The median age was 65 and the median digoxin dose and estimated glomerular filtration rate were 0.125 mg/d and 55 ml/min/1.73 m2, respectively. Digoxin dose was reduced in 16% of the patients, mainly due to high serum drug concentration or worsening renal function. The median duration of therapy was 5 months, with half of the patients stopping treatment, primarily due to physician preference. Significant arrhythmias developed in 11% of patients, almost exclusively in newly diagnosed patients. Arrhythmias presented as terminal events in five patients; four with bradycardia followed by pulseless electrical activity (PEA) with ventricular tachycardia/fibrillation (VT/VF) during resuscitation; all patients had acute renal failure and severe, decompensated heart failure. One patient had ventricular tachycardia as a terminal event. Only one patient was treated with digoxin antibody therapy.

CONCLUSIONS

Digoxin may be cautiously utilized in AL amyloidosis patients. We suggest its use in lower doses and frequent drug concentration monitoring along with close monitoring of electrolytes and renal function. Nonetheless, toxicity at low serum concentration cannot be excluded due to potential for toxic concentration at the tissue level and should be taken under consideration when prescribing digoxin for these patients. Studies with higher-level evidence are needed to confirm these findings.

Для цитирования: Muchtar Eli, Gertz Morie A, Kumar Shaji K, Lin Grace, Boilson Barry, Clavell Alfredo, Lacy Martha Q, Buadi Francis K, Hayman Suzanne R, Kapoor Prashant, Dingli David, Rajkumar S Vincent, Dispenzieri Angela, Grogan Martha. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2018. DOI: 10.1080/13506129.2018.1449744.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.